Vikrant Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 02-07-2024
- Paid Up Capital ₹ 1.00 Cr
as on 02-07-2024
- Company Age 33 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.93 Cr
as on 02-07-2024
- Satisfied Charges ₹ 2.20 Cr
as on 02-07-2024
- Revenue 79.72%
(FY 2022)
- Profit 24.10%
(FY 2022)
- Ebitda 373.45%
(FY 2022)
- Net Worth 15.99%
(FY 2022)
- Total Assets -15.87%
(FY 2022)
About Vikrant Life Sciences
The Corporate was formerly known as Vikrant Sales Pvt. Ltd.. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹3.93 Cr. The company has closed loans amounting to ₹2.20 Cr, as per Ministry of Corporate Affairs (MCA) records.
Pupi Koul, Varun Koul, and Vijay Koul serve as directors at the Company.
- CIN/LLPIN
U51397DL1991PTC045937
- Company No.
045937
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Oct 1991
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
North West Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Vikrant Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Varun Koul  | Director | 01-Oct-2006 | Current |
| Pupi Koul | Director | 08-Oct-1991 | Current |
| Vijay Koul | Director | 08-Oct-1991 | Current |
Financial Performance of Vikrant Life Sciences.
Vikrant Life Sciences Private Limited., for the financial year ended 2022, experienced significant growth in revenue, with a 79.72% increase. The company also saw a substantial improvement in profitability, with a 24.1% increase in profit. The company's net worth Soared by an impressive increase of 15.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vikrant Life Sciences?
In 2020, Vikrant Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 21 Oct 2019 | ₹0.55 M | Open |
Others Creation Date: 31 Jul 2018 | ₹3.80 Cr | Open |
Punjab National Bank Creation Date: 25 Mar 2014 | ₹0.70 M | Open |
How Many Employees Work at Vikrant Life Sciences?
Unlock and access historical data on people associated with Vikrant Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vikrant Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vikrant Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
